SPOTLIGHT: Parexel buys trial group

Parexel has agreed to buy California Clinical Trials Medical Group and Behavioral and Medical Research for $65 million. The operations offer specialty Phase I through IV clinical research services through four clinical sites in California. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.

The series C positions Lava to begin assessing the drugs in proof-of-concept clinical trials in solid tumors and hematological malignancies.